Revenue (Tables)

3 Months Ended

Mar. 31, 2022

Risks and Uncertainties [Abstract]

Disaggregation of Revenue

The following table and descriptions below show the products from which the Company generated its revenue:

	Three Months Ended March 31,
Revenue by product (in thousands)	2022		2021
MACI implants and kits
Implants based on contracted rates sold through a specialty pharmacy (a)	$	15,190	$	13,206
Implants subject to third party reimbursement sold through a specialty pharmacy (b)	3,369		4,280
Implants sold direct based on contracted rates (c)	5,634		4,466
Implants sold direct subject to third-party reimbursement (d)	861		849
Biopsy kits - direct bill	522		519
Change in estimates related to prior periods (e)	419		477
Total MACI implants and kits	25,995		23,797
Epicel
Direct bill (hospital)	9,857		9,830
NexoBrid revenue (f)	222		941
Total revenue	$	36,074	$	34,568
(a) Represents implants sold through Orsini and AllCare whereby such specialty pharmacies have a direct contract with the underlying insurance provider. The amount of reimbursement is based on contracted rates at the time of sale supported by the pharmacy’s direct contracts.
(b) Represents implants sold through Orsini or AllCare whereby such specialty pharmacy does not have a direct contract with the underlying payer. The amount of reimbursement is established based on a payer or state fee schedule and/or payer history.
(c) Represents implants sold directly from the Company to the facility based on a contract and known price agreed upon prior to the surgery date. Also represents direct sales under a contract to specialty distributor DMS.
(d) Represents implants sold directly from the Company to the facility based on a contract and known price agreed upon prior to the surgery date. The payment terms are subject to third-party reimbursement from an underlying insurance provider.
(e) Primarily represents changes in estimates related to implants sold through Orsini or AllCare in which such specialty pharmacy does not have a direct contract with the underlying payer. The initial estimate of the amount of reimbursement is established based on a payer or state fee schedule and/or payer history. The change in estimates is a result of additional information, changes in collection expectations or actual cash collections received in the current period.
(f) Represents revenue based on a percentage of gross profits for sales of NexoBrid to BARDA, pursuant to the license agreement between the Company and MediWound.